Stewart, J., Strickler, J., Mettu, N., MacLaughlan, S., Niedzwiecki, D., Levine, E., & Blazer, D. (2020). 409 A phase i trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO). In Regular and young investigator award abstracts (p. A248.2-A249). BMJ Publishing Group Ltd. https://doi.org/10.1136/jitc-2020-sitc2020.0409

Stewart, John, John Strickler, Niharika Mettu, Shannon MacLaughlan, Donna Niedzwiecki, Edward Levine, and Daniel Blazer. “409 A phase i trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO).” In Regular and Young Investigator Award Abstracts, A248.2-A249. BMJ Publishing Group Ltd, 2020. https://doi.org/10.1136/jitc-2020-sitc2020.0409.

Stewart J, Strickler J, Mettu N, MacLaughlan S, Niedzwiecki D, Levine E, et al. 409 A phase i trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO). In: Regular and young investigator award abstracts. BMJ Publishing Group Ltd; 2020. p. A248.2-A249.

Stewart, John, et al. “409 A phase i trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO).” Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, 2020, p. A248.2-A249. Crossref, doi:10.1136/jitc-2020-sitc2020.0409.

Stewart J, Strickler J, Mettu N, MacLaughlan S, Niedzwiecki D, Levine E, Blazer D. 409 A phase i trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO). Regular and young investigator award abstracts. BMJ Publishing Group Ltd; 2020. p. A248.2-A249.